This is a preview of subscription content, log in via an institution to check access.
Reference
NICE. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease Internet Document : Nov 2018. Available from: URL: https://www.nice.org.uk/guidance/gid-ta10286/documents/final-appraisal-determination-document
Rights and permissions
About this article
Cite this article
NICE recommends nivolumab for resected stage III and IV melanoma. PharmacoEcon Outcomes News 818, 38 (2018). https://doi.org/10.1007/s40274-018-5536-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5536-4